Venture Capital Pulse — 2026-04-24

Top Deals This Week

Kailera Therapeutics — $625M IPO Debut

• Sector: Biotech / GLP-1 therapeutics
• Lead investor(s): Public market investors
• What they do: GLP-1 drug developer targeting metabolic and obesity-related conditions
• Why it matters: Kailera's record-breaking biotech IPO is headlining April's resurgence of healthcare public listings, signaling that biotech markets are reopening after a prolonged drought — even as tech startups remain in wait-and-see mode

Era — $11M Seed Round

• Sector: AI hardware / software platform
• Lead investor(s): Not disclosed
• What they do: Era builds a software platform designed to run across multiple AI gadget form factors — glasses, rings, and pendants — betting that AI hardware will fragment into many wearable shapes
• Why it matters: The round is an early signal of conviction in the post-smartphone hardware thesis; investors are beginning to back the software layer that would make diverse AI wearables viable at scale

1 sources

techstartups.com

techstartups.com

Eli Lilly — $7B Acquisition (GLP-1 Hedge)

• Sector: Biopharma / M&A
• Lead investor(s): Eli Lilly (acquirer)
• What they do: Eli Lilly is hedging against a potential future GLP-1 revenue drop-off by acquiring a complementary biotech company at a $7 billion valuation
• Why it matters: The deal illustrates how large pharma incumbents are using M&A to extend their GLP-1 runway, creating exit opportunities for biotech VCs and bolstering confidence in life sciences dealmaking

Philadelphia Startup Ecosystem — $2.2B Q1 2026 VC Raised

• Sector: Regional / diversified
• Lead investor(s): Multiple institutional VCs
• What they do: Philly-area startups closed $2.2 billion across 150 deals in Q1 2026, a massive regional haul — though the capital was concentrated among a few companies, leaving most startups competing for a smaller share
• Why it matters: The Philadelphia data illustrates a broader national pattern: record aggregate totals mask extreme concentration at the top, a dynamic playing out in every major market this year

New Funds & LP Moves

• Bob Iger / Thrive Capital: Former Disney CEO Bob Iger has rejoined Thrive Capital as an advisor following his exit from Disney. Iger holds an equity stake in the firm and previously served as a venture partner. His return deepens Thrive's media and entertainment network at a moment when AI content and distribution deals are accelerating.

• General Catalyst (IPO Consideration): According to commentary this week, General Catalyst remains in early-stage deliberations about a potential IPO of the VC firm itself — a trend being watched closely by founders and LPs alike, as a public VC creates novel dynamics around fund deployment incentives, fee structures, and LP liquidity.

1 sources

techcrunch.com

techcrunch.com

Exits & Acquisitions

• Kailera Therapeutics (IPO): Kailera Therapeutics, a GLP-1 drug developer, debuted publicly with a $625 million raise — the record-breaking biotech IPO headlining April's selective resurgence. Biotech and healthcare are leading the IPO comeback while tech startups largely wait on the sidelines.

• Eli Lilly Acquisition ($7B): Eli Lilly completed a $7 billion acquisition to hedge against a potential GLP-1 revenue decline. The deal is the latest sign that pharma incumbents are using M&A aggressively to secure their next-generation pipelines, providing a meaningful liquidity event for biotech VCs holding positions in the target company.

Sector Spotlight: Biotech & Life Sciences — The IPO Window Cracks Open

Biotech and life sciences are the clear winner of this week's capital markets activity, with Kailera Therapeutics' $625M IPO standing as the most prominent data point. According to PitchBook, biotech and healthcare are leading April's IPO resurgence while tech names — most notably AI companies — continue to sit on the sidelines, still navigating valuation uncertainty tied to public market multiples.

Key companies driving the trend include Kailera (GLP-1), another unnamed protein biomarker detection company also advancing toward IPO, and Eli Lilly's aggressive M&A posture which is helping to underpin valuations across the sector. The Fierce Biotech Fundraising Tracker separately notes continued large-round activity ($50M+) in biopharma.

What this signals for founders and investors: The biotech IPO window is cracking open — but selectively. Only companies with differentiated clinical data and clear revenue pathways are clearing the bar. For VCs with biotech holdings, this represents the first meaningful exit liquidity in roughly 18 months. For AI-focused funds, the message is sobering: the public markets are not yet ready to price frontier AI companies, making secondary transactions and tender offers the primary liquidity mechanism for now.

What to Watch Next Week

• Mega-IPO Secondaries Reset: PitchBook reports that SpaceX, OpenAI, and Anthropic are all expected to go public within the coming year in record-breaking IPOs. Their exits would leave a significant hole in the VC secondaries market — watch for secondary pricing dislocations and LP rebalancing as this narrative develops.

• Cerebras S-1 Filing: AI chipmaker Cerebras filed its S-1 ahead of a planned IPO. Investors should watch early roadshow signals closely — the reception will serve as a crucial test of whether public markets are finally ready to price frontier AI infrastructure companies.

• OpenAI Life Sciences Push: PitchBook flagged this week that OpenAI's GPT-Rosalind initiative is heating up AI competition in life sciences, energizing biotech VCs who see foundation-model-powered drug discovery as the next capital concentration point. Monitor whether this catalyzes new fund launches or co-investment structures in the space.

• European VC Fundraising Recovery: PitchBook notes that European VC fundraising is recovering — but not for everyone. Expect continued bifurcation between top-quartile managers closing oversubscribed funds and mid-tier managers facing LP fatigue, particularly as global capital remains concentrated in AI and US-based managers.